Business Context and Reporting Period
Company: vTv Therapeutics Inc. (VTVT)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: vTv is a late-stage biopharmaceutical company developing oral, small molecule drug candidates for diabetes and chronic diseases. Its lead candidate, cadisegliatin, is a liver-selective glucokinase activator in Phase 3 trials for Type 1 Diabetes. The company operates as a holding company with vTv Therapeutics LLC as its principal operating subsidiary.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $36,839 | $0 |
| Operating Expenses | $13,576 | $6,503 |
| Operating Income | $23,263 | $(6,503) |
| Net Income (Attributable to vTv) | $24,134 | $(5,092) |
| Diluted EPS | $1.65 | $(0.77) |
| Cash and Cash Equivalents (End of Period) | $98,086 | $31,059 |
| Net Cash Provided by Operating Activities | $9,154 | $(5,687) |
| Total Assets | $98,813 | $89,899 |
| Accumulated Deficit | $(302,558) | $(326,692) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $0 in Q1 2025 to $36.8 million in Q1 2026. This was driven by two primary events:
- Recognition of a $20.0 million upfront fee from Newsoara Biopharma Co., Ltd. following a Second Amendment to their license agreement (expanding rights to global territories).
- Recognition of $16.9 million in license revenue from G42 Investments upon the lifting of contractual restrictions on intellectual property use.
- Profitability Shift: The company swung from a net loss of $5.1 million in Q1 2025 to a net income of $24.1 million in Q1 2026, primarily due to the non-recurring revenue recognition described above.
- Expense Growth: Operating expenses increased by $7.1 million (109%) year-over-year. Research and Development (R&D) expenses rose $6.1 million to $9.0 million, driven by increased clinical study costs for cadisegliatin and other projects. General and Administrative (G&A) expenses increased $0.9 million to $4.6 million.
- Liquidity Improvement: Cash and cash equivalents increased by $9.2 million during the quarter, ending at $98.1 million, compared to $31.1 million in the prior year period.
Guidance, Outlook, and Risks
- Clinical Progress: The FDA removed a clinical hold on the cadisegliatin program on March 14, 2025. The CATT1 Phase 3 trial is ongoing, with enrollment expected to complete in Q3 2026. A Phase 2 trial in Type 2 Diabetes with partner G42 is expected to start screening in 2026.
- Future Funding: Management anticipates continued losses and negative cash flows from operations in the future as clinical trials continue. The company expects to need substantial additional funding and is evaluating strategies including direct equity investments and further licensing.
- Capital Resources: As of March 31, 2026, the company has an accumulated deficit of $302.6 million. While current cash reserves are $98.1 million, the company has not generated product revenue and relies on financing and collaboration payments.
- Risks: Key risks include the uncertainty of clinical trial outcomes, the timing of regulatory approvals, the ability to secure additional capital, and the potential for dilution from future equity offerings. The company also faces risks related to the Tax Receivable Agreement with MacAndrews & Forbes, though no liability has been recognized to date.
Investor Verification Checklist
- Revenue Sustainability: Verify the non-recurring nature of the $36.8 million revenue (license fees vs. product sales) and assess the timeline for future milestone payments from Newsoara and G42.
- Cash Burn Rate: Analyze the run-rate of R&D expenses ($9.0M/quarter) against the $98.1M cash balance to estimate the runway without additional financing.
- Clinical Trial Status: Confirm the current enrollment status of the CATT1 trial and the specific timeline for top-line data, which triggers the expiration of certain warrants.
- Dilution Potential: Review the outstanding warrant positions (13.7 million warrants) and the ATM facility ($47.5M remaining) to understand potential future share count increases.
- Related Party Transactions: Monitor the Tax Receivable Agreement with MacAndrews & Forbes, which could impact future cash flows if Class B shares are exchanged for Class A shares.